Unique ID issued by UMIN | UMIN000043219 |
---|---|
Receipt number | R000049324 |
Scientific Title | Systemic therapy against unresectable hepatocellular carcinoma |
Date of disclosure of the study information | 2021/02/01 |
Last modified on | 2024/02/04 09:22:03 |
Systemic therapy against unresectable hepatocellular carcinoma
Systemic therapy against unresectable hepatocellular carcinoma
Systemic therapy against unresectable hepatocellular carcinoma
Systemic therapy against u-HCC
Japan |
hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
Evaluation for improving overall survival by systemic therapy in patients with unresectable HCC
Efficacy
Confirmatory
Pragmatic
Not applicable
Overall survival after introducing initial systemic treatment
Anti-tumor responses of systemic treatments (RECIT/ mRECIST), Progression free survival and time to progression of each systemic treatment, adverse events of each systemic treatment, relative changes of hepatic reserve function, nutritional status, tumor markers, physical conditions (muscle volume, muscle strength, body weight), adverse event
Observational
Not applicable |
Not applicable |
Male and Female
Patients with unresectable liver cancer who received systemic drug treatment
Patients who disagree with data use
1000
1st name | Atsushi |
Middle name | |
Last name | Hiraoka |
Ehime Prefectural Central Hospital
Gastroenterology Center
7900011
83 Kasuga-cho, Matsuyama, Ehime, Japan
81899471111
hirage@m.ehime-u.ac.jp
1st name | Atsushi |
Middle name | |
Last name | Hiraoka |
Ehime Prefectural Central Hospital
Gastroenterology Center
7900011
83 Kasuga-cho, Matsuyama, Ehime, Japan
81899471111
hirage@m.ehime-u.ac.jp
RELPEC and HCC48
none
Self funding
Ehime Prefectural Central Hospital
83 Kasuga-cho, Matsuyama, Ehime, Japan
81899471111
hirage@m.ehime-u.ac.jp
NO
2021 | Year | 02 | Month | 01 | Day |
https://www.eph.pref.ehime.jp/epch/patient/asset/30-66.pdf
Published
https://pubmed.ncbi.nlm.nih.gov/35666040/
251
Following adjustment with inverse probability weighting (IPW), Atez/Bev-group showed better PFS (0.5-/1-/1.5-years: 56.6%/31.6%/non-estimable vs. 48.6%/20.4%/11.2%, p < 0.0001) and OS rates (0.5-/1-/1.5-years: 89.6%/67.2%/58.1% vs. 77.8%/66.2%/52.7%, p = 0.002).
2024 | Year | 02 | Month | 04 | Day |
unresectable hepatocellular carcinoma patients treated with systemic chemotherapy
Enrollment of patients excluding those who did not consent to prospective backward-looking studies
none
PFS, OS
Completed
2021 | Year | 01 | Month | 19 | Day |
2021 | Year | 01 | Month | 22 | Day |
2022 | Year | 02 | Month | 01 | Day |
2022 | Year | 12 | Month | 31 | Day |
Observation study
2021 | Year | 02 | Month | 01 | Day |
2024 | Year | 02 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049324
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |